Light-responsive nanomaterials as nanomedicines: new approaches to treating macular degeneration, cancer and other critical unmet therapeutic needs. Nanotechnology is enabling new medicines for the treatment of important diseases such as cancer and macular degeneration. This project will investigate novel nanomaterials for the development of new highly effective medicines that can be controlled after administration, leading to reduced side effects and increased convenience for patients.
Targeting particulate carriers to epithelial M cells. This project aims to develop and validate an advanced in vitro model of the human intestinal epithelium. The intestine-on-chip model should enable mechanistic studies of the uptake of nano- and micron-size particles by intestinal cells and deliver new insights into the way particulate carriers can be specifically targeted and transported across the intestinal epithelium. Project knowledge and technology are anticipated to generate new commerc ....Targeting particulate carriers to epithelial M cells. This project aims to develop and validate an advanced in vitro model of the human intestinal epithelium. The intestine-on-chip model should enable mechanistic studies of the uptake of nano- and micron-size particles by intestinal cells and deliver new insights into the way particulate carriers can be specifically targeted and transported across the intestinal epithelium. Project knowledge and technology are anticipated to generate new commercialisation opportunities in the oral delivery industry and ultimately, should drive the development of efficient oral formulations for biologics. The model should also reduce the need for animal studies.Read moreRead less
Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and h ....Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and hence the risks of dose related side effects. This project has potential both to improve healthcare and to encourage the growth of expertise in the biotechnology industry in Australia.Read moreRead less
Topical peptide delivery for cosmetic and therapeutic benefits. Milk is a major Australian agricultural commodity and is now used in a number of topical products for the management of various skin conditions including chafing in babies, eczema and ageing skin. Hence, this work hopes to contribute to promoting and maintaining good health of Australians.
In addition, there is considerable research being conducted on peptide development for a range of diseases and there may be a possibility of ....Topical peptide delivery for cosmetic and therapeutic benefits. Milk is a major Australian agricultural commodity and is now used in a number of topical products for the management of various skin conditions including chafing in babies, eczema and ageing skin. Hence, this work hopes to contribute to promoting and maintaining good health of Australians.
In addition, there is considerable research being conducted on peptide development for a range of diseases and there may be a possibility of delivering these by the skin.
This work, in seeking to understand some of the fundamental determinants governing how exogenously applied peptides distribute in the skin, is also contributing to the development of Australian pharmaceutical and cosmetic industries.Read moreRead less
Harnessing lipid nano-assembly for next generation functional foods and pharmaceutical products. Nature assembles lipid molecules from our diet into useful structures in our gastrointestinal tract with remarkable precision and versatility. By understanding and harnessing these processes we can design new lipid-based nanomaterials leading to more effective functional foods and pharmaceutical products with reduced side effects.
Novel click assembled drug-polymer conjugates as next generation drug delivery systems. The purpose of the project is to develop previously inaccessible drug-polymer conjugates with tuneable and sustained drug release rates via a novel polymerisation approach. Ultimately, this will afford next-generation polymer therapeutics suitable for the treatment of a range of disorders and diseases, leading to improvements in heath care.
Physico-chemical and Biopharmaceutical Investigations of Novel Drug Delivery Systems for Oral Administration of Lipophilic Drugs. The new platform technology for carrying lipophilic molecules will be applicable to many molecules currently under development by Australian Industry and will inspire novel encapsulation approaches to new and existing drugs as well as functional foods and nutraceuticals. Improved oral bioavailability of anticancer drugs will improve the quality of life of patients, re ....Physico-chemical and Biopharmaceutical Investigations of Novel Drug Delivery Systems for Oral Administration of Lipophilic Drugs. The new platform technology for carrying lipophilic molecules will be applicable to many molecules currently under development by Australian Industry and will inspire novel encapsulation approaches to new and existing drugs as well as functional foods and nutraceuticals. Improved oral bioavailability of anticancer drugs will improve the quality of life of patients, reduce health care costs and provide broader benefits to the community. The Australian biotechnology/pharmaceutical industries can share in a greater proportion of the US$50 billion market for specialised drug delivery, which is increasing by 20% annually. Australia's scientific competitiveness will be strengthened in the fields of nano-encapsulation and colloidal delivery.Read moreRead less
Probiotic Prawn Oral Immunotherapy (ProPIT) For Treatment Of Prawn Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,865,369.00
Summary
A ‘curative’ food allergy treatment is needed to prevent deaths and improve care. We recently showed that probiotic peanut oral immunotherapy (PPOIT) was highly effective for treating peanut allergy. 82% of PPOIT treated children gained tolerance compared to 4% of the placebo group. We will now test the combined probiotic-food OIT approach for treating prawn allergy. If successful, we will have identified the first treatment for prawn allergy and a platform treatment for other food allergies.
A Physicochemical Approach for Optimizing Drug Delivery from BioSilicon. By applying modern techniques and a multidisciplinary approach, this research will develop an understanding of drug loading of BioSiliconTM at a molecular level. This novel class of nano-structured biomaterial has exciting potential for developing a range of controllable drug delivery systems. Existing medical applications of BioSilicon deliver only small molecules for very specialised uses. Current research has not focused ....A Physicochemical Approach for Optimizing Drug Delivery from BioSilicon. By applying modern techniques and a multidisciplinary approach, this research will develop an understanding of drug loading of BioSiliconTM at a molecular level. This novel class of nano-structured biomaterial has exciting potential for developing a range of controllable drug delivery systems. Existing medical applications of BioSilicon deliver only small molecules for very specialised uses. Current research has not focused on understanding the pore structure and how it can be adapted for special applications. Our research will create new drug delivery systems with many innovative applications in medical, veterinary and bio-diagnostics fields. The medical and socio-economic impacts will be internationally significant.Read moreRead less
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control the interface of materials with biological systems. The Centre will exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp of revol ....ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control the interface of materials with biological systems. The Centre will exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp of revolutionizing diagnosis and therapy in many diseases. The CoE will be the focus of bio-nano research activity in Australia, uniting universities, research agencies, institutes and companies. The expected outcomes are better diagnostic and therapeutic tools designed via an enhanced understanding of the bio-nano-interface.Read moreRead less